NCT06388902 2025-11-21
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
BioRay Pharmaceutical Co., Ltd.
Phase 1 Suspended
Clinical Trials
32 trialsNCT05938296 2025-11-19
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
Phase 1 Suspended
NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT05055518 2025-06-27
APL-102 Capsule in Patients With Advanced Solid Tumors
Apollomics Inc.
Phase 1 Suspended
NCT05958199 2025-06-27
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Phase 1 Suspended
NCT02354547 2025-05-30
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT05571969 2025-05-07
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Allarity Therapeutics
Phase 1 Suspended
NCT05191667 2025-02-13
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Suspended
NCT04120246 2024-07-10
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Veana Therapeutics
Phase 1 Suspended
NCT04714983 2024-04-09
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Phase 1 Suspended
NCT03932253 2024-03-27
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1 Suspended
NCT04711161 2024-01-23
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Green3Bio, Inc.
Phase 1 Suspended
NCT04996030 2024-01-23
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Syros Pharmaceuticals
Phase 1 Suspended
NCT04053062 2024-01-05
LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
Bioray Laboratories
Phase 1 Suspended
NCT03859752 2023-09-22
TR1801-ADC in Patients With Tumors That Express c-Met
Open Innovation Partners, Inc.
Phase 1 Suspended
NCT04650451 2023-04-20
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Bellicum Pharmaceuticals
Phase 1 Suspended
NCT03722186 2021-03-22
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Suspended
NCT03120130 2019-10-14
Amblyomin-X
União Química Farmacêutica Nacional S/A
Phase 1 Suspended
NCT02093871 2017-07-21
PISH-2
ThermalCore Inc
Phase 1 Suspended
NCT01762410 2014-09-29
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
Phase 1 Suspended
NCT01779336 2014-09-29
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
Phase 1 Suspended
NCT01337518 2012-12-18
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Enzon Pharmaceuticals, Inc.
Phase 1 Suspended
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00909558 2010-02-24
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Envita Medical Center, Inc.
Phase 1 Suspended
NCT00459823 2009-03-24
A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours
Eisai Inc.
Phase 1 Suspended
NCT00827203 2009-03-09
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Suspended
NCT00499499 2009-02-04
A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors
Eisai Inc.
Phase 1 Suspended
NCT00264472 2008-12-15
A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors
Adherex Technologies, Inc.
Phase 1 Suspended
NCT00753480 2008-11-07
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Genentech, Inc.
Phase 1 Suspended
NCT00460278 2008-06-04
Study of XL418 in Adults With Solid Tumors
Exelixis
Phase 1 Suspended
NCT00607711 2008-05-05
Study of Oral Palifosfamide Tris in Solid Tumors
Alaunos Therapeutics
Phase 1 Suspended
NCT00077493 2007-12-28
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
Phase 1 Suspended